共 50 条
- [2] EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDYHAEMATOLOGICA, 2017, 102 : 314 - 315Zinzani, P. L.Santoro, A.Leppa, S.Demeter, J.Follows, G. A.Lenz, G.Kim, W. S.Mollica, L.Nagler, A.Diong, C. P.Provenciio, M.Stevens, D. A.Trevarthen, D.Maagnoli, M.Cupit, L.Yin, S.Hiemeyer, F.Garcia-Vargas, J.Childs, B. H.Dreyling, M.
- [3] Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphomaBLOOD ADVANCES, 2021, 5 (03) : 823 - 828Panayiotidis, PanayiotisFollows, George A.Mollica, LuiginaNagler, ArnonOzcan, MuhitSantoro, ArmandoStevens, DonTrevarthen, DavidHiemeyer, FlorianGarcia-Vargas, JoseChilds, Barrett H.Zinzani, Pier LuigiDreyling, Martin
- [4] Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell LymphomaBLOOD, 2018, 132Dreyling, MartinSantoro, ArmandoMollica, LuiginaLeppa, SirpaFollows, George A.Lenz, GeorgKim, Won SeogNagler, ArnonPanayiotidis, PanayiotisDemeter, JuditOzcan, MuhitKosinova, MarinaBouabdallah, KrimoMorschhauser, FranckStevens, DonTrevarthen, DavidRodrigues, LianaHiemeyer, FlorianWang, MingLuGarcia-Vargas, JoseChilds, Barrett H.Zinzani, Pier Luigi
- [5] Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 studyANNALS OF ONCOLOGY, 2017, 28Provencio Pulla, M.Santoro, A.Mollica, L.Leppa, S.Follows, G.Lenz, G.Kim, W. S.Nagler, A.Panayiotidis, P.Demeter, J.Ozcan, M.Kosinova, M.Bouabdallah, K.Morschhauser, F.Ishida, T.Huang, L.Garcia-Vargas, J.Childs, B. H.Zinzani, P. L.Dreyling, M.
- [6] Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6-year follow-up of CHRONOS-1ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 51 - 52Dreyling, M.Santoro, A.Mollica, L.Leppa, S.Follows, G.Lenz, G.Kim, W. S.Nagler, A.Panayiotidis, P.Ozcan, M.Kosinova, M.Provencio, M.Magagnoli, M.Bouabdallah, K.Diong, C. PhippsMunoz, J.Cao, A.Hiemeyer, F.Odongo, F.Garcia-Vargas, J.Childs, B.Zinzani, P. L.
- [7] Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma: Primary results of the pivotal Chronos-1 studyCANCER RESEARCH, 2017, 77Dreyling, MartinSantoro, ArmandoMollica, LuiginaLeppa, SirpaFollows, George A.Lenz, GeorgKim, Won SeogNagler, ArnonPanayiotidis, PanayiotisDemeter, JuditOzcan, MuhitKosinova, MarinaBouabdallah, KrimoMorschhauser, FranckStevens, Don A.Trevarthen, DavidGiurescu, MariusKupit, LisaYin, ShuxinHiemeyer, FlorianGarcia-Vargas, JoseChilds, Barrett H.Zinzani, Pier Luigi
- [8] Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 studyONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 12 - 12Dreyling, M.Santoro, A.Mollica, L.Leppa, S.Follows, G. A.Lenz, G.Kim, W. S.Nagler, A.Panayiotidis, P.Demeter, J.Ozcan, M.Kosinova, M.Bouabdallah, K.Morschhauser, F.Stevens, D. A.Trevarthen, D.Giurescu, M.Kupit, L.Childs, B. H.Zinzani, P. L.
- [9] Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe ToxicitiesBLOOD, 2017, 130Dreyling, MartinSantoro, ArmandoMollica, LuiginaLeppa, SirpaFollows, GeorgeLenz, GeorgKim, Won SeogNagler, ArnonPanayiotidis, PanayiotisDemeter, JuditOzcan, MuhitKosinova, MarinaBouabdallah, KrimoMorschhauser, FranckStevens, Don A.Trevarthen, DavidMagagnoli, MassimoIshida, TatianeLu, CindyHiemeyer, FlorianMiriyala, AshokGarcia-Vargas, JoseChilds, Barrett H.Zinzani, Pier Luigi
- [10] Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 StudyBLOOD, 2018, 132Santoro, ArmandoMollica, LuiginaLeppa, SirpaFollows, George A.Lenz, GeorgKim, Won SeogNagler, ArnonDimou, MariaDemeter, JuditMagagnoli, MassimoRodrigues, LianaWirtz, OliverHiemeyer, FlorianLiu, LiKoechert, KarlGarcia-Vargas, JoseChilds, Barrett H.Zinzani, Pier LuigiDreyling, Martin H.